dm+d

Unassigned

New Medicines

Sickle cell disease in people experiencing vaso-occlusive crises

Information

New molecular entity
Global Blood Therapeutics
Global Blood Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A fully human monoclonal antibody targeting P-selectin, supplied as a 500mg in 10mL liquid concentrate for IV infusion.
SCD is thought to be the most common severe genetic disease in the UK and France, with 10,000-15,000 people affected. Vaso-occlusive crises (obstruction of the microcirculation by sickled red blood cells, causing ischaemia).is the most common type of crisis. It may be precipitated by cold, infection, dehydration, exertion or ischaemia. Over 90% of hospital admissions for patients with SCD are for painful crises, but nearly all sickle pain is coped with in the community [1].
Sickle cell disease in people experiencing vaso-occlusive crises
Intravenous infusion